Shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.24 and traded as low as $1.06. Akari Therapeutics shares last traded at $1.09, with a volume of 37,485 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on Akari Therapeutics in a research note on Friday. They issued a “sell” rating for the company.
View Our Latest Stock Report on AKTX
Akari Therapeutics Price Performance
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Why is the Ex-Dividend Date Significant to Investors?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
